Rallybio Corporation (RLYB)
Market Cap | 56.37M |
Revenue (ttm) | n/a |
Net Income (ttm) | -76.28M |
Shares Out | 41.45M |
EPS (ttm) | -1.87 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 46,114 |
Open | 1.360 |
Previous Close | 1.330 |
Day's Range | 1.330 - 1.380 |
52-Week Range | 1.155 - 6.330 |
Beta | -1.69 |
Analysts | Buy |
Price Target | 8.90 (+554.41%) |
Earnings Date | Aug 6, 2024 |
About RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical devel... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for RLYB stock is "Buy." The 12-month stock price forecast is $8.9, which is an increase of 554.41% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/p/y/conf5-2515010.jpg)
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
![](https://cdn.snapi.dev/images/v1/w/t/press20-2481811.jpg)
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
![](https://cdn.snapi.dev/images/v1/n/k/press20-2421619.jpg)
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
![](https://cdn.snapi.dev/images/v1/4/v/conf14-2414494.jpg)
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/w/k/press1-2376889.jpg)
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/p/k/press5-2366112.jpg)
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/s/p/press15-2350730.jpg)
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/f/l/press14-2319816.jpg)
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/q/f/conf9-2293301.jpg)
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/g/7/press18-2261874.jpg)
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready clinica...
![](https://cdn.snapi.dev/images/v1/f/l/press3-2216256.jpg)
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/s/t/press13-2203343.jpg)
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcut...
![](https://cdn.snapi.dev/images/v1/q/s/press5-2190207.jpg)
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/3/8/press15-2173537.jpg)
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary data from the completed multiple dose cohort of the Phase 1 safety and pharmacokinetics (PK) study fo...
![](https://cdn.snapi.dev/images/v1/l/u/press17-2149584.jpg)
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent program and corp...
![](https://cdn.snapi.dev/images/v1/k/1/conf14-2146800.jpg)
Rallybio to Present at Upcoming Investor Conferences in November
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/f/n/press12-2136358.jpg)
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study ha...
![](https://cdn.snapi.dev/images/v1/v/l/conf19-2087457.jpg)
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/6/y/press15-2047909.jpg)
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/o/7/conf9-2044621.jpg)
Rallybio to Present at Upcoming Investor Conferences in September
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/d/o/press12-2011713.jpg)
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the second quarter ended June 30, 2023 and provided an update on recent program and corporat...
![](https://cdn.snapi.dev/images/v1/s/b/conf1-2001190.jpg)
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/h/t/press8-1965802.jpg)
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract reporting results from the Phase 1 first-in-human single ascending dose clinical study of RLYB11...
![](https://cdn.snapi.dev/images/v1/m/j/press4-1952872.jpg)
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
![](https://cdn.snapi.dev/images/v1/o/7/press14-1946856.jpg)
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...